Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL5918793 | 1.00 | FFAR3 (0.54) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL1054733 | 1.00 | — | — | |
| Acetic Acid SCHEMBL10773161 | 1.00 | FFAR3 (0.54) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL2259927 | 1.00 | FFAR3 (0.54) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL19128777 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL3626183 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL4937602 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL17459497 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetic Acid SCHEMBL5182815 | 0.96 | FFAR3 (0.50) | FFAR3LCKFYNALDH1A1LMNA | |
| Acetone SCHEMBL28039834 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156840-A1 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE | GLENMARK SPECIALTY S.A. (CH) | 2024-05-16 | — | — | US | claimed |
| EP-3043773-B1 | STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE FOR NASAL ADMINISTRATION | GLENMARK SPECIALTY SA (CH) | 2021-06-30 | — | — | EP | claimed |
| EP-3718533-A1 | STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE | Glenmark Specialty S.A. (CH) | 2020-10-07 | — | — | EP | claimed |
| CN-107970244-B | Composition containing ciprofloxacin and dexamethasone and preparation method thereof | 武汉武药科技有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-10463674-B2 | Process for manufacturing sterile ophthalmic pharmaceutical suspensions | SENTISS PHARMA PRIVATE LIMITED (IN) | 2019-11-05 | — | — | US | claimed |
| US-9820991-B2 | Pharmaceutical composition comprising brinzolamide | SENTISS PHARMA PRIVATE LIMITED (IN) | 2017-11-21 | — | — | US | claimed |
| US-20160279139-A1 | AN IMPROVED PROCESS FOR MANUFACTURING STERILE OPHTHALMIC PHARMACEUTICAL SUSPENSIONS | SENTISS PHARMA PRIVATE LIMITED (IN) | 2016-09-29 | — | — | US | claimed |
| EP-3043773-A1 | STABLE FIXED DOSE PHARMACEUTICAL COMPOSITION COMPRISING MOMETASONE AND OLOPATADINE | Glenmark Specialty S.A. (CH) | 2016-07-20 | — | — | EP | claimed |
| US-20160175317-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BRINZOLAMIDE | SENTISS PHARMA PVT. LTD. (IN) | 2016-06-23 | — | — | US | claimed |
| US-20150133409-A1 | TOPICAL OPHTHALMIC, OTIC, AND NASAL COMPOSITIONS OF CIPROFLOXACIN | PARIKH NILESH (US) | 2015-05-14 | — | — | US | claimed |
| EP-1819362-B1 | TOPICAL NEPAFENAC FORMULATIONS | ALCON INC (CH) | 2010-08-04 | — | — | EP | claimed |
| EP-1819362-A2 | TOPICAL NEPAFENAC FORMULATIONS | ALCON INC. (CH) | 2007-08-22 | — | — | EP | claimed |
| US-20060122277-A1 | Topical nepafenac formulations | ALCON, INC. | 2006-06-08 | — | — | US | claimed |
| WO-2006060618-A2 | TOPICAL NEPAFENAC FORMULATIONS | ALCON, INC. (CH) | 2006-06-08 | — | — | WO | claimed |
| EP-1214056-B1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | ALCON INC (CH) | 2003-10-29 | — | — | EP | claimed |
| EP-1214056-A1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | Alcon Universal, Ltd. (CH) | 2002-06-19 | — | — | EP | claimed |
| US-6359016-B2 | FOR EYES, EARS OR NOSES | ALCON UNIVERSAL LTD. (CH) | 2002-03-19 | — | — | US | claimed |
| US-20010049366-A1 | Topical solution formulations containing an antibiotic and a corticosteroid | ALCON UNIVERSAL LTD. | 2001-12-06 | — | — | US | claimed |
| US-20010034339-A1 | Topical suspension formulations containing ciprofloxacin and dexamethasone | NOVARTIS AG (CH) | 2001-10-25 | — | — | US | claimed |
| WO-2001022936-A1 | TOPICAL SUSPENSION FORMULATIONS CONTAINING CIPROFLOXACIN AND DEXAMETHASONE | ALCON UNIVERSAL LTD. (CH) | 2001-04-05 | — | — | WO | claimed |